Status:

COMPLETED

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

Lead Sponsor:

Vyne Therapeutics Inc.

Conditions:

Papulopustular Rosacea

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.

Detailed Description

This is an open-label, multicenter, 40-week extension study to evaluate the long-term safety, tolerability, and efficacy of FMX103 1.5% topical foam in the treatment of moderate-to-severe facial papul...

Eligibility Criteria

Inclusion

  • Have completed 12 weeks of treatment in either Study FX2016-11 or Study FX2016-12.
  • Have not had a worsening of disease, determined by the Investigator's Global Assessment (IGA), at Visit 5/Week 12 (Final Visit) relative to the Day 0/Baseline assessment in Study FX2016-11 or Study FX2016-12.

Exclusion

  • Have a new systemic disease or condition, including an ongoing AE that might interfere with the conduct of the study or the interpretation of results.
  • Have developed a condition that would have been exclusionary for Study FX2016-11 or Study FX2016-12, including pseudomembranous colitis, antibiotic associated colitis, hepatitis, liver damage, renal impairment, drug addiction, or alcohol abuse.

Key Trial Info

Start Date :

September 5 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 15 2019

Estimated Enrollment :

504 Patients enrolled

Trial Details

Trial ID

NCT03276936

Start Date

September 5 2017

End Date

January 15 2019

Last Update

January 18 2022

Active Locations (79)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 20 (79 locations)

1

Foamix Investigational Site # 207

Glendale, Arizona, United States, 85308

2

Foamix Investigational Site # 202

Hot Springs, Arkansas, United States, 71913

3

Foamix Investigational Site # 222

Rogers, Arkansas, United States, 72758

4

Foamix Investigational Site # 127

Fremont, California, United States, 94538